# 3SBio

Source: https://onco.cc/companies/3sbio/  
OnCo record `3sbio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.

## Summary

3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. In May 2025 it licensed SSGJ-707, its bispecific antibody against PD-1 and VEGF, to Pfizer for development outside China, where Pfizer calls it PF-08634404; the licence took effect in July 2025 with a USD 1.25 billion upfront payment, up to USD 4.8 billion in milestones and an option for Pfizer to add China.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Shenyang Sunshine Pharmaceutical; Sansheng Pharmaceutical
- Tags: ctgov-sponsor; china
- HQ: Shenyang, China
- Type: biotech
- Website: https://www.3sbio.com
- Ticker: 1530.HK

## Notes

- Freshened 29 October 2026: Pfizer licence terms confirmed from Pfizer's 2025 Form 10-K and 3SBio's HKEX announcements of 20 May and 24 July 2025. 3SBio was not acquired; its 2025-2026 HKEX filings also propose a separate Hong Kong listing of its subsidiary Mandi, which was not read further.

## Sources

- Official website: https://www.3sbio.com
- HKEX: licence agreement for SSGJ-707 with Pfizer coming into effect (24 July 2025): https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0724/2025072401558.pdf
- Pfizer Form 10-K for 2025 (SEC): https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Inetetamab](https://onco.cc/drugs/inetetamab/), [PF-08634404](https://onco.cc/drugs/pf-08634404/), [SSGJ-612](https://onco.cc/drugs/ssgj-612/), [SSGJ-705](https://onco.cc/drugs/ssgj-705/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers](https://onco.cc/trials/nct07233850/), [A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients](https://onco.cc/trials/nct07171606/), [Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain](https://onco.cc/trials/nct07008703/), [SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07022002/), [SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07646626/), [SSGJ-707 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06980272/)

---
JSON: https://onco.cc/api/v1/entities/3sbio.json